MTOR and kidney angiomyolipoma: The effectiveness of oral mTOR inhibitors for the treatment of TSC-related manifestations is established for subependymal giant cell astrocytoma (SEGA), renal angiomyolipoma, lymphangioleiomyomatosis (LAM), epilepsy, cardiac rhabdomyoma, and skin lesions [10–15].